Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections

PHASE4SuspendedINTERVENTIONAL
Enrollment

760

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
GonorrheaChlamydiaSyphilisSexually Transmitted Infections (STIs)
Interventions
DRUG

Doxycycline hyclate delayed released 200 mg

200 mg of doxycycline taken by mouth as soon as possible and within 72 hours after any condomless oral, vaginal, and/or anal sex.

DRUG

Doxycycline hyclate delayed released 200 mg weekly

200 mg of doxycycline taken by mouth weekly regardless of sexual activity

Trial Locations (11)

10011

Callen-Lorde Community Health Center, New York

10027

Harlem Prevention Center, New York

19104

Penn Prevention, Philadelphia

20010

Children's National Medical Center, Washington D.C.

27599

Chapel Hill, Chapel Hill

30303

Ponce de Leon, Atlanta

38015

St. Jude Children's Research Hospital, Memphis

60612

University Illinois Chicago, Chicago

70112

Tulane University, New Orleans

77030

Baylor College of Medicine, Houston

90095

UCLA Care, Los Angeles

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)/Division of AIDS (DAIDS)

UNKNOWN

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Florida State University

OTHER

lead

Westat

OTHER

NCT06738407 - Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections | Biotech Hunter | Biotech Hunter